[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356696-105":59,"doc-detail-356696-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","mettl3-in-esophageal-cancer-current-insights-into-molecular-mechanisms-subtype-heterogeneity-and-targeted-therapy-prospects-review","METTL3 in esophageal cancer - Current insights into molecular mechanisms, subtype heterogeneity and targeted therapy prospects - Review","","Esophageal cancer (EC), comprising esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC), urgently requires novel targeted therapies. The m6A methyltransferase METTL3 is a key epitranscriptomic regulator in gastrointestinal malignancies. In ESCC, METTL3 promotes tumor progression via m6A-dependent control of RNA stability, splicing, and translation through networks including NOTCH1, EGR1/Snail, and Wnt/β-catenin, while EC-related m6A-independent or immune-checkpoint hypotheses remain unvalidated. METTL3 also shapes DNA damage repair and radiotherapy resistance, offering a therapeutic vulnerability, whereas EAC METTL3 biology is insufficiently characterized.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mettl3-in-esophageal-cancer-current-insights-into-molecular-mechanisms-subtype-heterogeneity-and-targeted-therapy-prospects-review/356696/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mettl3-in-esophageal-cancer-current-insights-into-molecular-mechanisms-subtype-heterogeneity-and-targeted-therapy-prospects-review/356696.png","ImageObject",300,407,{"name":92,"@type":93},"Angel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What roles does METTL3 play in esophageal squamous cell carcinoma (ESCC)?","Question",{"text":112,"@type":113},"In ESCC, METTL3 predominantly acts as an oncogene, driving tumor progression by m6A-dependent regulation of RNA stability, splicing, and translation through key signaling networks.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Are METTL3-related immune-checkpoint mechanisms in esophageal cancer validated?",{"text":117,"@type":113},"No. Hypotheses regarding m6A-independent functions or direct immune-checkpoint regulation by METTL3 in esophageal cancer remain unvalidated.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is METTL3 considered a potential therapeutic vulnerability in EC?",{"text":121,"@type":113},"METTL3 actively modulates DNA damage repair and radiotherapy resistance, which suggests a promising target under therapeutic stress, though clinical pharmacological development is still at an early stage.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356696,1790495546,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687207412472,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","INTERNATIONAL JOURNAL OF ONCOLOGY 68: 71, 2026  \nMETTL3 in esophageal cancer: Current insights into molecular mechanisms, subtype heterogeneity and targeted therapy prospects (Review)  \nCHUNLAN PU 1* , HUAN HU 1* , HENGRUI FAN 1 , TAO CHEN2 and JIAO TANG2  \n1Medical Research Center, The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu,  \n2  \nChengdu, Sichuan 610031, P.R. China; Department of Laboratory Medicine, Xindu District People's Hospital,  \nChengdu, Sichuan 610500, P.R. China  \nReceived January 22, 2026; Accepted April 7, 2026  \nDOI: 10.3892/ijo.2026.5884  \nAbstract. Esophageal cancer (EC), comprising esophageal squamous cell carcinoma (ESCC) and esophageal adenocar‑ cinoma (EAC), urgently requires novel targeted therapies . The m6A methyltransferase METTL3 has emerged as a critical epitranscriptomic regulator in gastrointestinal malig‑ nancies. In ESCC, METTL3 functions predominantly as an oncogene, driving tumor progression via m6A‑dependent modulation of RNA stability, splicing, and translation across key networks, including NOTCH1, EGR1/Snail and Wnt/β‑catenin. Conversely, hypotheses regarding m6A‑inde‑ pendent functions or direct immune‑checkpoint regulation remain unvalidated in EC. Crucially, METTL3 actively modulates DNA damage repair and radiotherapy resistance, exposing a promising therapeutic vulnerability, although clinical pharmacological development remains nascent . Furthermore, METTL3 biology in EAC remains conspicu‑ ously uncharacterized. By strictly stratifying evidence by EC subtype, the present review distinguishes empirically validated mechanisms from premature cross‑cancer extrapo‑ lations . Ultimately, a novel conceptual framework that redefines METTL3 not merely as a static oncogene, but as  \nCorrespondence to: Dr Chunlan Pu, Medical Research Center, The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, 82 Qinglong Street, Qingyang, Chengdu, Sichuan 610031, P.R. China  \nE‑mail: [chunlanpu@swjtu.edu.cn](chunlanpu@swjtu.edu.cn)  \nDr Jiao Tang, Department of Laboratory Medicine, Xindu District People's Hospital, Xindu District People's Hospital, 199 Yuying Road, Xindu, Chengdu, Sichuan 610500, P.R. China  \nE‑mail: [tjsyfmm123@163.com](tjsyfmm123@163.com)  \n*Contributed equally  \nKey words: methyltransferase‑like 3, N6‑methyladenosine, esophageal cancer, esophageal squamous cell carcinoma, esophageal adenocarcinoma, epitranscriptomics, targeted therapy  \na dynamic, context‑dependent regulatory hub, is proposed. Under therapeutic stress, METTL3 amplifies cellular phenotypic plasticity, systematically orchestrating tumor adaptation and treatment resistance.  \nContents  \n1. Introduction  \n2. METTL3 expression and clinical significance in EC  \n3. METTL3‑mediated regulatory mechanisms  \n4. METTL3‑driven malignant phenotypes in ESCC  \n5. Therapeutic targeting of METTL3 in EC  \n6. Rationale against the extrapolation of ESCC‑derived METTL3 biology to EAC  \n7. Challenges and future directions  \n8. Conclusion  \n1. Introduction  \nEsophageal cancer (EC) is a highly aggressive malignancy, ranking among the leading causes of cancer‑related mortality worldwide, with over 600,000 new cases and 500,000 deaths estimated annually (1) . EC comprises two major histological subtypes, esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC), which differ substantially in geographic distribution, etiologic factors, molecular features and clinical behaviors. ESCC predomi‑ nates in East Asia, East Africa and Central Asia, whereas the incidence of EAC continues to increase in numerous Western countries (2‑4). Because early‑stage EC is frequently asymptomatic, most patients present with advanced disease, resulting in dismal prognoses despite multimodal interven‑ tions (5,6). Current standard‑of‑care relies heavily on surgery, chemotherapy, radiotherapy, and, in selected settings, immune checkpoint blockade (7,8) . Nevert","cbCailzjTiGsY0z4","https://ap.wps.com/l/cbCailzjTiGsY0z4","pdf",3782125,15,"English","# Contents\n## 1. Introduction\n## 2. METTL3 expression and clinical significance in EC\n## 3. METTL3-mediated regulatory mechanisms\n## 4. METTL3-driven malignant phenotypes in ESCC\n## 5. Therapeutic targeting of METTL3 in EC\n## 6. Rationale against the extrapolation of ESCC-derived METTL3 biology to EAC\n## 7. Challenges and future directions\n## 8. Conclusion","[{\"question\":\"What roles does METTL3 play in esophageal squamous cell carcinoma (ESCC)?\",\"answer\":\"In ESCC, METTL3 predominantly acts as an oncogene, driving tumor progression by m6A-dependent regulation of RNA stability, splicing, and translation through key signaling networks.\"},{\"question\":\"Are METTL3-related immune-checkpoint mechanisms in esophageal cancer validated?\",\"answer\":\"No. Hypotheses regarding m6A-independent functions or direct immune-checkpoint regulation by METTL3 in esophageal cancer remain unvalidated.\"},{\"question\":\"Why is METTL3 considered a potential therapeutic vulnerability in EC?\",\"answer\":\"METTL3 actively modulates DNA damage repair and radiotherapy resistance, which suggests a promising target under therapeutic stress, though clinical pharmacological development is still at an early stage.\"}]","METTL3 in esophageal cancer - Current insights into molecular mechanisms, subtype heterogeneity and targeted therapy prospects - Review | PDF",1790126828,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f5f6438de95d60c3b0f6f07cacb478d2.webp",983,1357,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dac125d2e431c300fee964afbc4eb521.webp",982,1356,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/313354a7db8ade27d0cc8528a59ac0e1.webp",981,1354,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/61ac633f8c6c17d4010239cf1d5184e9.webp",980,1353]